BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 31462146)

  • 21. Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Boom V; Anton J; Lahdenne P; Quartier P; Ravelli A; Wulffraat NM; Vastert SJ
    Pediatr Rheumatol Online J; 2015 Dec; 13():55. PubMed ID: 26634252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paediatric rheumatic disease: Diagnosing macrophage activation syndrome in systemic JIA.
    Vastert SJ; Prakken BJ
    Nat Rev Rheumatol; 2014 Nov; 10(11):640-2. PubMed ID: 25201384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Different Diagnostic Guidelines for the Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: Single Centre Experience.
    Jelušić M; Kronja M; Frković M; Sršen S; Huljev Frković S; Štekić Novački K
    Acta Clin Croat; 2018 Jun; 57(2):307-311. PubMed ID: 30431724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary varicella infection in children with systemic juvenile idiopathic arthritis under tocilizumab therapy.
    Nozawa T; Nishimura K; Ohara A; Hara R; Ito S
    Mod Rheumatol; 2019 May; 29(3):558-562. PubMed ID: 27846755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are the 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome applicable to patients with adult-onset Still's disease?
    Tada Y; Inokuchi S; Maruyama A; Suematsu R; Sakai M; Sadanaga Y; Ono N; Arinobu Y; Koarada S
    Rheumatol Int; 2019 Jan; 39(1):97-104. PubMed ID: 30051293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
    Yokota S; Itoh Y; Morio T; Sumitomo N; Daimaru K; Minota S
    J Rheumatol; 2015 Apr; 42(4):712-22. PubMed ID: 25684767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombotic Microangiopathy Associated with Macrophage Activation Syndrome: A Multinational Study of 23 Patients.
    Minoia F; Tibaldi J; Muratore V; Gallizzi R; Bracaglia C; Arduini A; Comak E; Vougiouka O; Trauzeddel R; Filocamo G; Mastrangelo A; Micalizzi C; Kasapcopur O; Unsal E; Kitoh T; Tsitsami E; Kostik M; Schmid JP; Prader S; Laube G; Maritsi D; Jelusic M; Shenoi S; Vastert S; Ardissino G; Cron RQ; Ravelli A;
    J Pediatr; 2021 Aug; 235():196-202. PubMed ID: 33836183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Minoia F; Davì S; Horne A; Bovis F; Demirkaya E; Akikusa J; Ayaz NA; Al-Mayouf SM; Barone P; Bica B; Bolt I; Breda L; De Cunto C; Enciso S; Gallizzi R; Griffin T; Hennon T; Horneff G; Jeng M; Kapovic AM; Lipton JM; Magni Manzoni S; Rumba-Rozenfelde I; Magalhaes CS; Sewairi WM; Stine KC; Vougiouka O; Weaver LK; Davidsone Z; De Inocencio J; Ioseliani M; Lattanzi B; Tezer H; Buoncompagni A; Picco P; Ruperto N; Martini A; Cron RQ; Ravelli A; ; ; ;
    J Rheumatol; 2015 Jun; 42(6):994-1001. PubMed ID: 25877504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ.
    Put K; Avau A; Brisse E; Mitera T; Put S; Proost P; Bader-Meunier B; Westhovens R; Van den Eynde BJ; Orabona C; Fallarino F; De Somer L; Tousseyn T; Quartier P; Wouters C; Matthys P
    Rheumatology (Oxford); 2015 Aug; 54(8):1507-17. PubMed ID: 25767156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proceedings from the 2
    Canna SW; Schulert GS; de Jesus A; Pickering A; Brunner H; Gadina M; Levine S; Goldbach-Mansky R; Boutelle J; Sinha R; DeBenedetti F; Grom A;
    Pediatr Rheumatol Online J; 2020 Jul; 18(Suppl 1):53. PubMed ID: 32664935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performances of the "MS-score" And "HScore" in the diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis patients.
    Sag E; Keskin A; Atalay E; Demir S; Cuceoglu MK; Akca UK; Batu ED; Bilginer Y; Ozen S
    Rheumatol Int; 2021 Jan; 41(1):87-93. PubMed ID: 33215249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis.
    Lehmberg K; Pink I; Eulenburg C; Beutel K; Maul-Pavicic A; Janka G
    J Pediatr; 2013 Jun; 162(6):1245-51. PubMed ID: 23333131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An unusual presentation of purine nucleoside phosphorylase deficiency mimicking systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.
    Arduini A; Marasco E; Marucci G; Pardeo M; Insalaco A; Caiello I; Moneta GM; Prencipe G; De Benedetti F; Bracaglia C
    Pediatr Rheumatol Online J; 2019 May; 17(1):25. PubMed ID: 31118063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Takakura M; Shimizu M; Irabu H; Sakumura N; Inoue N; Mizuta M; Nakagishi Y; Yachie A
    Clin Immunol; 2019 Nov; 208():108252. PubMed ID: 31449879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.
    Toplak N; Blazina Š; Avčin T
    Drug Des Devel Ther; 2018; 12():1633-1643. PubMed ID: 29922038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis.
    Chen G; Deutsch GH; Schulert GS; Zheng H; Jang S; Trapnell B; Lee PY; Macaubas C; Ho K; Schneider C; Saper VE; de Jesus AA; Krasnow MA; Grom A; Goldbach-Mansky R; Khatri P; Mellins ED; Canna SW
    Arthritis Rheumatol; 2022 Jul; 74(7):1271-1283. PubMed ID: 35189047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma exchange successfully treated macrophage activation syndrome in rheumatoid factor-positive polyarticular juvenile idiopathic arthritis with co-existing pneumonia.
    Shi L; Hu F; Xu C; Zhu H; Qie D; Yuan C; Tao Y; Liu H
    Int J Rheum Dis; 2018 May; 21(5):1142-1145. PubMed ID: 28328098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.
    Schulert GS; Yasin S; Carey B; Chalk C; Do T; Schapiro AH; Husami A; Watts A; Brunner HI; Huggins J; Mellins ED; Morgan EM; Ting T; Trapnell BC; Wikenheiser-Brokamp KA; Towe C; Grom AA
    Arthritis Rheumatol; 2019 Nov; 71(11):1943-1954. PubMed ID: 31379071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic onset juvenile idiopathic arthritis: a single center experience.
    Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
    Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble CD25 in serum: a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis.
    Reddy VV; Myles A; Cheekatla SS; Singh S; Aggarwal A
    Int J Rheum Dis; 2014 Mar; 17(3):261-7. PubMed ID: 24417800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.